HENDERSON, NV / ACCESSWIRE / April 16, 2019 / CBD is becoming a household name in the US. In a recent survey conducted with the Harris Poll, Quartz asked over 2,000 Americans about their use and perceptions of CBD. The results show that the vast majority of people in the US are aware of the cannabis-derived compound: some 86% of survey takers had heard of CBD. Walgreens made big news announcing it will sell CBD creams, patches and sprays in nearly 1,500 stores in select states.
Companies positioned to capture this spending are worth your due diligence. A top opportunity in the space is brand building, consumer product cannabis play is Real Brands, Inc. (RLBD). RLBD has strong management with a solid background in branding and the beverage industry and plans to expand their holdings focusing on at least three CBD Categories: smokables, edibles and topical balms and lotions. The company recently updated their logo and brand identity. It is also developing an E-Commerce website and plans to launch it during the early part of the second quarter on their newly acquired domain name, to support online sales of a variety of smokable, edible, and topical CBD derived from hemp-based products for each of their brands. Start your research today.
Today we are highlighting: Real Brands, Inc. (RLBD), GW Pharmaceuticals plc (GWPH), Cara Therapeutics, Inc. (CARA), AXIM® Biotechnologies, Inc. (AXIM), and mCig, Inc. (MCIG).
Real Brands, Inc. (RLBD) (Market Cap: $12.405M; Share Price: $0.093) is launching a several CBD brands in 2019. The audit on the horizon means this could also be another major event for investors to pay attention to. Real Brands is first and foremost a marketing and branding company, which has been slowly building its portfolio of trademarked brand names that could each represent on their own major partnerships and joint ventures going forward. It is focused on the hemp-derived CBD Industry and is developing consumer products in the following categories- smokables, edibles and topicals.
Jerry Pearring, the CEO of Real Brands commented, "As the demand for CBD infused products continues to grow, we intend to create marketing strategies in at least three CBD Categories: smokables, edibles and topical balms and lotions."
_________
OTHER CANNABIS COS TO RESEARCH INCLUDE:
GW Pharmaceuticals plc (GWPH) (Market Cap: $5.027B; Share Price: $164.39), the world leader in the development and commercialization of cannabinoid prescription medicines, recently announced the appointment of Darren Cline as its new U.S. Chief Commercial Officer. Mr. Cline will lead the Epidiolex® U.S. commercial organization and is expected to start on April 22, 2019.
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.
GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a U.S. Phase 3 trial. The company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia.
________
Cara Therapeutics, Inc. (CARA) (Market Cap: $768.805M; Share Price: $19.44), a clinical-stage biopharmaceutical company, has a comprehensive report issued by Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies. Cara Therapeutics focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors.
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells.
________
AXIM® Biotechnologies, Inc. (AXIM) (Market Cap: $79.394M; Share Price: $1.30), a world leader in cannabinoid research and development, announced recently that the company's Chief Technology Officer, Lekhram Changoer, spoke at the "Believe" National Convention held by Kannaway®, the first hemp lifestyle network to offer cannabidiol ("CBD") hemp botanical products, on April 13, 2019 in San Diego.
Axim Biotechnologies, Inc., a biotechnology company, researches, develops, produces, and sells pharmaceutical, nutraceutical and cosmetic, and genetically controlled botanical products. It also engages in the extraction and purification of cannabinoids technologies based on its proprietary technologies. The company sells its products through Internet, direct-to-consumer health and wellness stores, collectives, cooperatives, and affiliate sales and master distributors. It is a world leader in the research and development of cannabinoid-based pharmaceutical and nutraceutical products. Along with building a robust intellectual property portfolio, AXIM is focused on clinical development programs that bring more efficacy and/or lower side effects than existing alternatives and require small to medium budgets and timelines to bring to market which presents a high added-value to the pharmaceutical field.
________
mCig Inc. (MCIG) (Market Cap: $61.416M; Share Price: $0.1188), a leading distributor of innovative products, customized packaging solutions, technologies, and services for the global medical cannabis industry, is pleased to announce recently that the company has received approval from the Financial Industry Regulatory Authority for the Obitx, Inc. dividend, and spinoff to MCIG's shareholders. It recently announced that its wholly-owned subsidiary, CBJ Distributing, is expanding its sales reach by introducing to its clients in Nevada and California a new in-house developed product line of hemp pre-rolled cigarettes and CBD vape pens with a proprietary terpene rich formula.
mCig Inc. operates in the cannabis industry in the United States and internationally. The company operates through four segments: Cultivation, Manufacturing and Distribution (CMD), Retail Sales, Media and Technologies, and Agriculture. The CMD segment designs, develops, engineers, and constructs modular buildings and green houses that assist cannabis and herbal growers in the market, as well as offers consulting services in the cannabis industry.
_________
Signed by
Priyanka Goel, CFA
Legal Disclaimer:
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to a three-month term consulting agreement with RLBD dated 8/31/18. The agreement calls for $100,000 note issued to Regal Consulting, and 2,500,000 restricted 144 shares of RLBD for three months of service. Regal has elected to convert $73,000 of principal of the $100,000 note into 2,761,872 Restricted 144 shares of RLBD. Regal Consulting has agreed to a twelve- month term consulting agreement with RLBD dated 1/4/2019. The agreement calls for $10,000 in cash and 500,000 shares per month. All payments were made directly by Real Brands, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. RLBD was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Full Legal Disclaimer Click Here.
Contact Information:
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Email: [email protected]
Phone: 1-702-720-6310
Country: United States
SOURCE: ACR Communication LLC